OUR PURPOSE IS SIMPLE:
Patients fighting chronic diseases are often denied access to life-saving treatments.
ICERWatch gives patients a voice to fight back.
Patients Rising NOW Comments on Draft Evidence Report “Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy: Effectiveness and Value”
Patients Rising NOW offers the following comments on ICER’s May 22nd draft report, “Deflazacort, Eteplirsen, and Golodirsen for Duchenne Muscular Dystrophy.” Our comments about the
Their kids have a rare and fatal disease. ICER President Dr. Steve Pearson believes Duchenne moms shouldn’t get a “vote” on their kids’ treatment.
Citing its impact on “health care insurance costs,” the Institute for Clinical and Economic Review has issued its dreaded insurance profitability “alert” for two new treatments for peanut allergies. ICER’s report encourages insurance companies to deny coverage and impose substantial barriers for patients seeking access to the treatments.
July is the month where we as a nation commemorate the Declaration of Independence of our country. On July 4, 1776 the Continental Congress declared